Clinics in dermatology最新文献

{"title":"Cover 2 - Editorial Board with barcode","authors":"","doi":"10.1016/S0738-081X(26)00259-2","DOIUrl":"10.1016/S0738-081X(26)00259-2","url":null,"abstract":"","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"44 5","pages":"Page IFC"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149159014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arriving at a definition of cutaneous paraneoplastic syndromes: A historic perspective on paraneoplasia","authors":"Shawn Afvari BS,&nbsp;Jane M. Grant-Kels MD","doi":"10.1016/j.clindermatol.2026.07.017","DOIUrl":"10.1016/j.clindermatol.2026.07.017","url":null,"abstract":"<div><div>Paraneoplastic syndromes are clinical manifestations resulting from the immune system’s response to an underlying malignancy. Over the past three centuries, significant advancements in understanding cutaneous paraneoplastic syndromes have emerged, from early historical observations by pioneers like Armand Trousseau and Ferdinand von Hebra to more modern figures like Grant J. Anhalt. The roles of cytokines, growth factors, and immune pathways in these syndromes have enhanced our knowledge of tumor-host interactions and driven the development of targeted therapies that address the underlying malignancy and associated cutaneous symptoms. Despite these advancements, cutaneous paraneoplastic syndromes remain underrecognized in clinical practice. Recognizing the cutaneous manifestations that signal the possibility of an underlying malignancy enables early detection and intervention. Here, we review the definition and criteria of cutaneous paraneoplastic syndromes and historical context.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"44 5","pages":"Pages 688-694"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sherlock Holmes and the last Nazi doctor","authors":"Leonard J. Hoenig MD,&nbsp;Philip R. Cohen MD, MS,&nbsp;John E. Wolf Jr MD, MA,&nbsp;Lawrence Charles Parish MD, MD (Hon), FRCP (Edin)","doi":"10.1016/j.clindermatol.2026.05.004","DOIUrl":"10.1016/j.clindermatol.2026.05.004","url":null,"abstract":"<div><div>In this contribution, we present an original modern-day detective story that we have created based upon Sherlock Holmes and Dr John H. Watson, both fictional characters created by the British author and physician, Sir Arthur Conan Doyle (1859-1930). In our tale, an elderly woman is slowly going deaf and experiencing vertigo. Her physicians are unable to determine the etiology of her symptoms but suspect that she was exposed to an ototoxic agent while a prisoner at the Ravensbrück concentration camp during World War II. The patient was a forced subject in Nazi medical experiments, but theNazis destroyed the information about thems at the War’s end. Holmes and Watson travel to Germany to interview the last living Nazi doctor in a desperate effort to save the lives of the patient, and possibly other family member, by finding out exactly what ototoxic agent was injected into the patient while she was an inmate at Ravensbrück. All the characters in this story are fictitious as are the details of the Nazi medical experiment described herein. In a postscript to this contribution, we address internet speculation concerning whether such an experiment took place at Ravensbrück.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"44 5","pages":"Pages 873-878"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148004978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The dermatologist can be a main character in nonmedical books: A succinct review of fiction novels, including a summary about their authors, in which a dermatologist is either the protagonist, antagonist, or deuteragonist","authors":"Philip R. Cohen MD, MS,&nbsp;Leonard J. Hoenig MD,&nbsp;Lawrence Charles Parish MD, MD (Hon), FRCP (Edin)","doi":"10.1016/j.clindermatol.2026.08.003","DOIUrl":"10.1016/j.clindermatol.2026.08.003","url":null,"abstract":"<div><div>Authors of fiction are unique. They develop the characters of their novels for their readers, with the main character of a book being the protagonist. Other important characters include the antagonist and the deuteragonist. This paper focuses on fiction novels in which one of the key characters is a dermatologist. Biographic sketches that describe some of the features of the authors who write these novels are provided. The authors include nine nonmedical writers: Sue Civil-Brown, Tom Jordon, Janice Kaplan, Lynn Schnurnberger, Carolyn See, Terry Southern, Camy Tang, Bruce Wagner, and Sheila Gewirtzman. They also include a nondermatologist physician (Sara Cohen who is a physiatrist and writes under the pseudonym Freida McFadden), and dermatologists Terry Cronin and Garry Gewirtzman (who writes with his wife Sheila, who is an accountant). A total of 10 dermatologists are included in the 18 books in which a dermatologist is a main character; one author wrote three books that had the same dermatologist as a protagonist, and a husband and wife team of writers wrote a series of seven novels in which a dermatologist was featured. The fictional dermatologists were either the protagonist (seven dermatologists in 15 novels), the antagonist (two dermatologists), or the deuteragonist (one dermatologist). The 18 novels were written by 12 authors. Nine of the authors had not attended medical school; however, three of the authors were physicians. Seven books were written by a husband and wife team (a dermatologist and his accountant wife). One book was written by two women who were not physicians. The dermatologist is a man as in six of the dermatologists or a women as in four of the dermatologists. All four of the women dermatologists were characters in novels written by women (five authors). The six men were included in books by either a man (four authors) or a woman (one author) or coauthors (including both a man and a woman). Some writers publish their novels under a pseudonym, with the authors having various personal reasons for using a pen name. Six of the 12 (50%) of the authors who wrote a novel with a dermatologist as the main character either used a pseudonym in that novel, or a different book, or both. Many of the nonphysician authors (five of nine, 56%) used a pen name; these included three women and two men. Only the woman physician author used a pseudonym. One of the men used a shortened version of his first name and did not include the suffix after his last name; both of the men did not include their middle name or the first letter of their middle name. The dermatologist—as either a protagonist, an antagonist, or a deuteroantagonist—provides the reader with an intriguing character in a novel.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"44 5","pages":"Pages 791-808"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reactive granulomatous dermatitis as a paraneoplastic phenomenon","authors":"Shawn Afvari BS,&nbsp;Esewi Aifuwa BSE,&nbsp;Jane M. Grant-Kels MD","doi":"10.1016/j.clindermatol.2026.07.023","DOIUrl":"10.1016/j.clindermatol.2026.07.023","url":null,"abstract":"<div><div>Reactive granulomatous dermatitis (RGD) represents a broad group of cutaneous inflammatory skin conditions including interstitial granulomatous dermatitis (IGD), palisaded neutrophilic and granulomatous dermatitis (PNGD), and interstitial granulomatous drug reaction (IGDR). These conditions are frequently associated with autoimmune disorders and secondary to medications. They can also present as paraneoplastic syndromes. RGD usually presents as erythematous papules, plaques, or nodules, distributed symmetrically, especially on the inner aspect of the arms and thighs, the flank of the trunk, the lower part of the abdomen, and intertriginous areas like the axilla. Histologically, IGD classically reveals interstitial histiocyte and lymphocyte infiltration, plus multinucleated giant cells. As a paraneoplastic disease, IGD may occur in myelodysplastic syndromes, leukemias, and such solid tumors found in the breast and lungs. The successful diagnosis of IGD relies on both histopathologic examination and clinical evaluation. Although administration of corticosteroids can offer symptomatic relief of the skin lesions, treatment requires addressing the underlying condition when identified. Awareness of RGD’s potential as an early marker for systemic disease, especially malignancy, is important for diagnostic and interventional purposes.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"44 5","pages":"Pages 747-752"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome: An emerging autoinflammatory paraneoplastic disorder","authors":"Ryan Chen BA,&nbsp;Kevin Fettel MSc,&nbsp;Goranit Sakunchotpanit BS,&nbsp;Richard Tran BA,&nbsp;Brianna Spiegel BS,&nbsp;Maya Akbik BS,&nbsp;Vinod E. Nambudiri MD, MBA, EdM","doi":"10.1016/j.clindermatol.2026.07.024","DOIUrl":"10.1016/j.clindermatol.2026.07.024","url":null,"abstract":"<div><div>VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a novel autoinflammatory disorder caused by somatic mutations in the UBA1 gene. It predominantly affects older me, although cases in women with X-chromosome mosaicism have been reported in the literature. Dermatologic manifestations, found in up to 90% of cases, are significant diagnostic clues and may include erythematous plaques, Sweet syndrome-like lesions, and livedo reticularis. VEXAS syndrome poses significant diagnostic challenges due to its overlap with hematologic, autoimmune, and inflammatory disease. Hallmark findings include macrocytic anemia, myeloid vacuolization, and the presence of UBA1 mutations. Current treatment options include corticosteroids, biologics, and hematopoietic stem cell transplantation, but data on long-term efficacy are limited. Advances in understanding the epidemiology, pathophysiology, and treatment of VEXAS syndrome will be essential for improving diagnostic accuracy and patient outcomes.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"44 5","pages":"Pages 760-769"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-kosher collagen products for patients practicing Judaism: Addressing religious concerns","authors":"Isha Gandhi BS,&nbsp;Robert Adler BA,&nbsp;Deena Fayyad BS,&nbsp;Chase Fishman,&nbsp;John Goncalves DO,&nbsp;Jessica Lori Feig MD, PhD","doi":"10.1016/j.clindermatol.2026.03.006","DOIUrl":"10.1016/j.clindermatol.2026.03.006","url":null,"abstract":"<div><div>Collagen-based therapies have become a driving force in antiaging procedures and wound healing<span><span>¹</span></span>; however, many formulations are derived from porcine or bovine sources that may not meet kosher dietary standards. Even products marketed as “kosher” may not satisfy the requirements of <em>halakha</em> (Jewish law) regarding slaughter and supervision.<span><span>²</span></span> How should dermatologists counsel observant Jewish patients regarding collagen options that align with their faith while ensuring optimal outcomes?</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"44 5","pages":"Pages 809-811"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aesthetic interventions in patients with allergic skin diseases: Risk assessment and evidence-based preventive risk management","authors":"İçim Kömürcügil Yiğit MD,&nbsp;Ümit Türsen MD,&nbsp;Belma Türsen MD,&nbsp;Berna Solak MD,&nbsp;Özge Sevil Karstarlı Bakay MD,&nbsp;George Kroumpouzos MD, PhD","doi":"10.1016/j.clindermatol.2026.03.001","DOIUrl":"10.1016/j.clindermatol.2026.03.001","url":null,"abstract":"<div><div>The use of aesthetic dermatologic procedures in patients with underlying allergic and inflammatory skin diseases is on the rise, but specific safety considerations are often overlooked. Individuals with hypersensitivity to injectables, chronic inducible urticaria, allergic contact dermatitis, atopic dermatitis, or hereditary angioedema may face an increased risk of adverse reactions triggered by mechanical trauma, injected substances, or disruption of the skin barrier. Adverse reactions to local anesthetics are predominantly non-IgE-mediated. Thus, preventive strategies should focus on selecting the appropriate agents and employing proper injection techniques rather than routine pharmacologic prophylaxis. Botulinum toxin, hyaluronic acid fillers, and hyaluronidase can rarely cause immediate or delayed hypersensitivity reactions. This highlights the need for individualized risk assessment and avoidance of reexposure in confirmed cases. For patients with chronic inducible urticaria, aesthetic procedures can act as physical triggers. Ensuring optimal disease control with preprocedural antihistamines may help reduce this risk. In cases of allergic contact dermatitis and atopic dermatitis, a compromised skin barrier and exposure to device-related allergens may heighten the chances of developing eczematous or infectious complications. Patients with hereditary angioedema require short-term prophylaxis, preferably utilizing C1-inhibitor therapy. With careful evaluation and tailored preventive strategies, aesthetic dermatologic procedures can be performed safely in patients with allergic and inflammatory skin conditions.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"44 5","pages":"Pages 820-828"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147462749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethical conflicts of the relative value unit system","authors":"Rebecca Kann BA,&nbsp;Esewi Aifuwa MD,&nbsp;Shawn Afvari MD,&nbsp;Jane M. Grant-Kels MD","doi":"10.1016/j.clindermatol.2026.02.014","DOIUrl":"10.1016/j.clindermatol.2026.02.014","url":null,"abstract":"<div><div>Ethical conflicts of interest can arise when productivity–based compensation models, particularly relative value units, intersect with clinical decision making in dermatology. Relative value units were designed to standardize physician work and serve as a metric for physician productivity and efficiency; however, they may influence how clinicians navigate treatment choices by prioritizing quantity over quality and incentivizing overuse. These dynamics can increase physician burnout and raise important concerns related to beneficence and justice. We outline these ethical considerations and propose strategies to maintain patient-centered care within productivity-driven systems.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"44 5","pages":"Pages 840-842"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147275463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Limberg rhomboid flap: History, creator, and importance in plastic surgery","authors":"Alberto Goldman MD, PhD,&nbsp;Uwe Wollina MD","doi":"10.1016/j.clindermatol.2026.01.013","DOIUrl":"10.1016/j.clindermatol.2026.01.013","url":null,"abstract":"<div><div>The Limberg rhomboid flap, first described in 1928 by the Russian surgeon Alexander Alexandrovich Limberg (1894-1974), represents a milestone in reconstructive plastic surgery. Based on precise geometric principles, the flap has become one of the most versatile and widely used techniques for closing skin defects across various body regions, particularly for treating pilonidal sinus. This contribution revisits the history of its creation, its mathematical planning, its technical and scientific principles, and its contemporary relevance in surgical and reconstructive practice.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"44 5","pages":"Pages 787-790"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146099902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}